Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1998 2
1999 7
2000 7
2001 4
2002 2
2004 2
2005 2
2006 2
2007 2
2008 3
2009 3
2010 4
2011 2
2012 3
2013 4
2014 4
2015 6
2016 3
2017 4
2018 3
2019 4
2020 4
2021 6
2022 3
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents.
Riether C, Pabst T, Höpner S, Bacher U, Hinterbrandner M, Banz Y, Müller R, Manz MG, Gharib WH, Francisco D, Bruggmann R, van Rompaey L, Moshir M, Delahaye T, Gandini D, Erzeel E, Hultberg A, Fung S, de Haard H, Leupin N, Ochsenbein AF. Riether C, et al. Among authors: ochsenbein af. Nat Med. 2020 Sep;26(9):1459-1467. doi: 10.1038/s41591-020-0910-8. Epub 2020 Jun 29. Nat Med. 2020. PMID: 32601337 Clinical Trial.
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, Früh M, Joerger M, Lardinois D, Gelpke H, Mauti LA, Britschgi C, Weder W, Peters S, Mark M, Cathomas R, Ochsenbein AF, Janthur WD, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M; Swiss Group for Clinical Cancer Research (SAKK). Rothschild SI, et al. Among authors: ochsenbein af. J Clin Oncol. 2021 Sep 10;39(26):2872-2880. doi: 10.1200/JCO.21.00276. Epub 2021 Jul 12. J Clin Oncol. 2021. PMID: 34251873 Free article. Clinical Trial.
Tumour mutations in long noncoding RNAs enhance cell fitness.
Esposito R, Lanzós A, Uroda T, Ramnarayanan S, Büchi I, Polidori T, Guillen-Ramirez H, Mihaljevic A, Merlin BM, Mela L, Zoni E, Hovhannisyan L, McCluggage F, Medo M, Basile G, Meise DF, Zwyssig S, Wenger C, Schwarz K, Vancura A, Bosch-Guiteras N, Andrades Á, Tham AM, Roemmele M, Medina PP, Ochsenbein AF, Riether C, Kruithof-de Julio M, Zimmer Y, Medová M, Stroka D, Fox A, Johnson R. Esposito R, et al. Among authors: ochsenbein af. Nat Commun. 2023 Jun 8;14(1):3342. doi: 10.1038/s41467-023-39160-7. Nat Commun. 2023. PMID: 37291246 Free PMC article.
Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities.
Esposito R, Polidori T, Meise DF, Pulido-Quetglas C, Chouvardas P, Forster S, Schaerer P, Kobel A, Schlatter J, Kerkhof E, Roemmele M, Rice ES, Zhu L, Lanzós A, Guillen-Ramirez HA, Basile G, Carrozzo I, Vancura A, Ullrich S, Andrades A, Harvey D, Medina PP, Ma PC, Haefliger S, Wang X, Martinez I, Ochsenbein AF, Riether C, Johnson R. Esposito R, et al. Among authors: ochsenbein af. Cell Genom. 2022 Aug 22;2(9):100171. doi: 10.1016/j.xgen.2022.100171. eCollection 2022 Sep 14. Cell Genom. 2022. PMID: 36778670 Free PMC article.
Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
Pabst T, Vey N, Adès L, Bacher U, Bargetzi M, Fung S, Gaidano G, Gandini D, Hultberg A, Johnson A, Ma X, Müller R, Nottage K, Papayannidis C, Recher C, Riether C, Shah P, Tryon J, Xiu L, Ochsenbein AF. Pabst T, et al. Among authors: ochsenbein af. Haematologica. 2023 Jul 1;108(7):1793-1802. doi: 10.3324/haematol.2022.281563. Haematologica. 2023. PMID: 36779592 Free PMC article. Clinical Trial.
Neutralizing antiviral antibody responses.
Zinkernagel RM, LaMarre A, Ciurea A, Hunziker L, Ochsenbein AF, McCoy KD, Fehr T, Bachmann MF, Kalinke U, Hengartner H. Zinkernagel RM, et al. Among authors: ochsenbein af. Adv Immunol. 2001;79:1-53. doi: 10.1016/s0065-2776(01)79001-3. Adv Immunol. 2001. PMID: 11680006 Free PMC article. Review.
Dendritic cell-based immunotherapy for myeloid leukemias.
Schürch CM, Riether C, Ochsenbein AF. Schürch CM, et al. Among authors: ochsenbein af. Front Immunol. 2013 Dec 31;4:496. doi: 10.3389/fimmu.2013.00496. Front Immunol. 2013. PMID: 24427158 Free PMC article. Review.
MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma.
Yang H, Gao Y, Xu D, Xu K, Liang SQ, Yang Z, Scherz A, Hall SRR, Forster S, Berezowska S, Yao F, Ochsenbein AF, Marti TM, Kocher GJ, Schmid RA, Dorn P, Peng RW. Yang H, et al. Among authors: ochsenbein af. Cell Death Discov. 2023 Feb 10;9(1):55. doi: 10.1038/s41420-023-01307-2. Cell Death Discov. 2023. PMID: 36765038 Free PMC article.
85 results